Which has preferable valuation & earnings, HCM or PHAT?

HUTCHMED has higher revenue and earnings than Phathom Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 4.67 $456.91M N/A N/A Phathom Pharmaceuticals $239.66M 2.50 -$221.25M -$1.28 N/A

Is HCM or PHAT more profitable?

HUTCHMED has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%. Company Net Margins Return on Equity Return on Assets HUTCHMED N/A N/A N/A Phathom Pharmaceuticals -41.34% N/A -20.81%

Does the media refer more to HCM or PHAT?

In the previous week, Phathom Pharmaceuticals had 2 more articles in the media than HUTCHMED. MarketBeat recorded 8 mentions for Phathom Pharmaceuticals and 6 mentions for HUTCHMED. Phathom Pharmaceuticals' average media sentiment score of 0.55 beat HUTCHMED's score of 0.37 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Phathom Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to OCUL or PHAT?

In the previous week, Ocular Therapeutix and Ocular Therapeutix both had 8 articles in the media. Phathom Pharmaceuticals' average media sentiment score of 0.55 beat Ocular Therapeutix's score of 0.54 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Phathom Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, PHAT or TRLV?

Trulieve Cannabis has higher revenue and earnings than Phathom Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phathom Pharmaceuticals $239.66M 2.50 -$221.25M -$1.28 N/A Trulieve Cannabis $1.14B 1.74 N/A N/A N/A

Is PHAT or TRLV more profitable?

Trulieve Cannabis has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%. Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals -41.34% N/A -20.81% Trulieve Cannabis N/A N/A N/A

Does the media prefer PHAT or TRLV?

In the previous week, Phathom Pharmaceuticals had 1 more articles in the media than Trulieve Cannabis. MarketBeat recorded 8 mentions for Phathom Pharmaceuticals and 7 mentions for Trulieve Cannabis. Phathom Pharmaceuticals' average media sentiment score of 0.55 beat Trulieve Cannabis' score of 0.40 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Trulieve Cannabis 1 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PHAT or TRVI?

In the previous week, Phathom Pharmaceuticals had 6 more articles in the media than Trevi Therapeutics. MarketBeat recorded 8 mentions for Phathom Pharmaceuticals and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.56 beat Phathom Pharmaceuticals' score of 0.55 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Phathom Pharmaceuticals (PHAT) Competitors

$7.40 +0.04 (+0.53%)

As of 11:40 AM Eastern

Compare

PHAT vs. HCM, OCUL, TRLV, PBH, and TRVI

Should you buy Phathom Pharmaceuticals stock or one of its competitors? Phathom Pharmaceuticals's main competitors and comparable companies include HUTCHMED (HCM), Ocular Therapeutix (OCUL), Trulieve Cannabis (TRLV), Prestige Consumer Healthcare (PBH), and Trevi Therapeutics (TRVI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Phathom Pharmaceuticals compare to HUTCHMED?

HUTCHMED (NASDAQ:HCM) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Phathom Pharmaceuticals had 2 more articles in the media than HUTCHMED. MarketBeat recorded 8 mentions for Phathom Pharmaceuticals and 6 mentions for HUTCHMED. Phathom Pharmaceuticals' average media sentiment score of 0.55 beat HUTCHMED's score of 0.37 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phathom Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

HUTCHMED has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%

HUTCHMED has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

HUTCHMED has higher revenue and earnings than Phathom Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	4.67	$456.91M	N/A	N/A
Phathom Pharmaceuticals	$239.66M	2.50	-$221.25M	-$1.28	N/A

HUTCHMED currently has a consensus target price of $14.87, suggesting a potential upside of 1.23%. Phathom Pharmaceuticals has a consensus target price of $21.25, suggesting a potential upside of 187.20%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Phathom Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Phathom Pharmaceuticals beats HUTCHMED on 8 of the 13 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Phathom Pharmaceuticals has higher revenue and earnings than Ocular Therapeutix. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	33.26	-$265.94M	-$1.42	N/A
Phathom Pharmaceuticals	$239.66M	2.50	-$221.25M	-$1.28	N/A

In the previous week, Ocular Therapeutix and Ocular Therapeutix both had 8 articles in the media. Phathom Pharmaceuticals' average media sentiment score of 0.55 beat Ocular Therapeutix's score of 0.54 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Phathom Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Ocular Therapeutix currently has a consensus target price of $25.75, indicating a potential upside of 227.32%. Phathom Pharmaceuticals has a consensus target price of $21.25, indicating a potential upside of 187.20%. Given Ocular Therapeutix's higher possible upside, equities research analysts plainly believe Ocular Therapeutix is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Phathom Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Phathom Pharmaceuticals has a net margin of -41.34% compared to Ocular Therapeutix's net margin of -579.10%. Phathom Pharmaceuticals' return on equity of 0.00% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-579.10%	-59.89%	-45.99%
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%

Ocular Therapeutix has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 3.1% of Ocular Therapeutix shares are held by insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Phathom Pharmaceuticals beats Ocular Therapeutix on 11 of the 16 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Trulieve Cannabis?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Trulieve Cannabis (NYSE:TRLV) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

Phathom Pharmaceuticals currently has a consensus price target of $21.25, suggesting a potential upside of 187.20%. Trulieve Cannabis has a consensus price target of $15.00, suggesting a potential upside of 45.35%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Phathom Pharmaceuticals is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 3.8% of Trulieve Cannabis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Trulieve Cannabis has higher revenue and earnings than Phathom Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$239.66M	2.50	-$221.25M	-$1.28	N/A
Trulieve Cannabis	$1.14B	1.74	N/A	N/A	N/A

In the previous week, Phathom Pharmaceuticals had 1 more articles in the media than Trulieve Cannabis. MarketBeat recorded 8 mentions for Phathom Pharmaceuticals and 7 mentions for Trulieve Cannabis. Phathom Pharmaceuticals' average media sentiment score of 0.55 beat Trulieve Cannabis' score of 0.40 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Trulieve Cannabis	1 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Trulieve Cannabis has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%
Trulieve Cannabis	N/A	N/A	N/A

Summary

Phathom Pharmaceuticals beats Trulieve Cannabis on 9 of the 12 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Prestige Consumer Healthcare?

Prestige Consumer Healthcare (NYSE:PBH) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 1.5% of Prestige Consumer Healthcare shares are owned by insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Prestige Consumer Healthcare has a net margin of 15.57% compared to Phathom Pharmaceuticals' net margin of -41.34%. Prestige Consumer Healthcare's return on equity of 11.39% beat Phathom Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	15.57%	11.39%	5.66%
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%

Prestige Consumer Healthcare has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.09B	2.02	$190.30M	$3.57	12.99
Phathom Pharmaceuticals	$239.66M	2.50	-$221.25M	-$1.28	N/A

Prestige Consumer Healthcare has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

In the previous week, Phathom Pharmaceuticals had 1 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 8 mentions for Phathom Pharmaceuticals and 7 mentions for Prestige Consumer Healthcare. Phathom Pharmaceuticals' average media sentiment score of 0.55 beat Prestige Consumer Healthcare's score of 0.42 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prestige Consumer Healthcare	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phathom Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Prestige Consumer Healthcare presently has a consensus price target of $67.67, suggesting a potential upside of 45.88%. Phathom Pharmaceuticals has a consensus price target of $21.25, suggesting a potential upside of 187.20%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Phathom Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Phathom Pharmaceuticals beats Prestige Consumer Healthcare on 9 of the 17 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Trevi Therapeutics?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Trevi Therapeutics (NASDAQ:TRVI) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Comparatively, 15.4% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Phathom Pharmaceuticals had 6 more articles in the media than Trevi Therapeutics. MarketBeat recorded 8 mentions for Phathom Pharmaceuticals and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.56 beat Phathom Pharmaceuticals' score of 0.55 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevi Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Phathom Pharmaceuticals has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Trevi Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%. Phathom Pharmaceuticals' return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%
Trevi Therapeutics	N/A	-23.59%	-22.64%

Phathom Pharmaceuticals currently has a consensus target price of $21.25, suggesting a potential upside of 187.20%. Trevi Therapeutics has a consensus target price of $27.08, suggesting a potential upside of 86.49%. Given Phathom Pharmaceuticals' higher possible upside, equities analysts plainly believe Phathom Pharmaceuticals is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Trevi Therapeutics has lower revenue, but higher earnings than Phathom Pharmaceuticals. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$239.66M	2.50	-$221.25M	-$1.28	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A

Summary

Trevi Therapeutics beats Phathom Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Phathom Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHAT vs. The Competition

Export

Metric	Phathom Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$601.50M	$12.51B	$7.27B	$13.16B
Dividend Yield	N/A	2.62%	2.52%	14.18%
P/E Ratio	-5.81	792.37	274.09	25.77
Price / Sales	2.50	842.09	655.31	90.20
Price / Cash	N/A	91.32	80.06	52.35
Price / Book	-1.21	10.61	10.52	6.38
Net Income	-$221.25M	$2.84B	$3.50B	$360.31M
7 Day Performance	5.85%	-1.18%	-1.03%	-1.33%
1 Month Performance	-19.40%	-1.51%	-3.91%	-3.88%
1 Year Performance	-37.14%	0.41%	13.11%	4.16%

Phathom Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHAT Phathom Pharmaceuticals	3.3677 of 5 stars	$7.40 +0.5%	$21.25 +187.2%	-35.0%	$601.50M	$239.66M	N/A	371	News Coverage
HCM HUTCHMED	1.3728 of 5 stars	$14.48 +5.9%	$14.87 +2.7%	-9.6%	$2.38B	$548.51M	N/A	1,796	Gap Down
OCUL Ocular Therapeutix	2.7731 of 5 stars	$9.99 flat	$25.75 +157.8%	-37.2%	$2.19B	$51.95M	N/A	325	Analyst Forecast Options Volume
TRLV Trulieve Cannabis	3.3094 of 5 stars	$11.49 +3.8%	$15.00 +30.5%	N/A	$2.13B	N/A	N/A	5,000	Gap Down
PBH Prestige Consumer Healthcare	3.5067 of 5 stars	$46.83 +4.1%	$70.75 +51.1%	-24.5%	$2.13B	$1.10B	13.12	890	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHAT) was last updated on 9/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phathom Pharmaceuticals (PHAT) Competitors

PHAT vs. HCM, OCUL, TRLV, PBH, and TRVI

How does Phathom Pharmaceuticals compare to HUTCHMED?

Summary

How does Phathom Pharmaceuticals compare to Ocular Therapeutix?

Summary

How does Phathom Pharmaceuticals compare to Trulieve Cannabis?

Summary

How does Phathom Pharmaceuticals compare to Prestige Consumer Healthcare?

Summary

How does Phathom Pharmaceuticals compare to Trevi Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT vs. The Competition

Phathom Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phathom Pharmaceuticals (PHAT) Competitors

PHAT vs. HCM, OCUL, TRLV, PBH, and TRVI

How does Phathom Pharmaceuticals compare to HUTCHMED?

Do institutionals and insiders hold more shares of HCM or PHAT?

Does the media refer more to HCM or PHAT?

Is HCM or PHAT more profitable?

Which has more risk & volatility, HCM or PHAT?

Which has preferable valuation & earnings, HCM or PHAT?

Do analysts prefer HCM or PHAT?

Summary

How does Phathom Pharmaceuticals compare to Ocular Therapeutix?

Which has better valuation & earnings, OCUL or PHAT?

Does the media refer more to OCUL or PHAT?

Do analysts prefer OCUL or PHAT?

Is OCUL or PHAT more profitable?

Which has more risk and volatility, OCUL or PHAT?

Do insiders & institutionals believe in OCUL or PHAT?

Summary

How does Phathom Pharmaceuticals compare to Trulieve Cannabis?

Do analysts recommend PHAT or TRLV?

Do insiders & institutionals have more ownership in PHAT or TRLV?

Which has better valuation and earnings, PHAT or TRLV?

Does the media prefer PHAT or TRLV?

Is PHAT or TRLV more profitable?

Summary

How does Phathom Pharmaceuticals compare to Prestige Consumer Healthcare?

Do institutionals and insiders hold more shares of PBH or PHAT?

Is PBH or PHAT more profitable?

Which has stronger earnings & valuation, PBH or PHAT?

Which has more volatility & risk, PBH or PHAT?

Does the media refer more to PBH or PHAT?

Do analysts recommend PBH or PHAT?

Summary

How does Phathom Pharmaceuticals compare to Trevi Therapeutics?

Do institutionals & insiders hold more shares of PHAT or TRVI?

Does the media prefer PHAT or TRVI?

Which has more risk & volatility, PHAT or TRVI?

Is PHAT or TRVI more profitable?

Do analysts rate PHAT or TRVI?

Which has higher earnings & valuation, PHAT or TRVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT vs. The Competition

Phathom Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools